Atypical hyperplasia of the breast: cancer risk-reduction strategies With the launch of LATUDA, a new treatment option for patients with schizophrenia in China, along with another atypical antipsychotic LONASEN already launched in February 2018, Sumitomo Dainippon Pharma expects to make a greater contribution to the treatment of patients with …

